# COVID-19 and Seasonal Influenza: Interim Guidance for Health Care and Public Health Providers

**VACCINATION**

## Table 3.1 CCHCS COVID-19 Vaccines: Information and Side Effects

<table>
<thead>
<tr>
<th>Vaccine Manufacturer</th>
<th>Pfizer-BioNTech</th>
<th>Moderna</th>
<th>Johnson &amp; Johnson (J&amp;J) (also known as Janssen)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Delivery</strong></td>
<td>Intramuscular (IM)</td>
<td>IM</td>
<td>IM</td>
</tr>
<tr>
<td><strong>Type of Vaccine</strong></td>
<td>mRNA</td>
<td>mRNA</td>
<td>Adenovirus vector</td>
</tr>
<tr>
<td><strong>Dosage</strong></td>
<td>0.3 mL</td>
<td>0.5 mL</td>
<td>0.5 mL</td>
</tr>
<tr>
<td><strong>Indicated Ages</strong></td>
<td>16+ years</td>
<td>18+ years</td>
<td>18+ years</td>
</tr>
<tr>
<td><strong>Vaccine Schedule</strong></td>
<td>Two doses separated by 21 days*</td>
<td>Two doses separated by 28 days*</td>
<td>One dose</td>
</tr>
</tbody>
</table>
| **Side Effects**      | Pain at the injection site: 84%  
                        | Fatigue: 63%  
                        | Headache: 55%  
                        | Muscle pains: 38%  
                        | Chills: 32%  
                        | Joint pains: 24%  
                        | Fever: 14%  | Pain at the injection site: 92%  
                        | Fatigue: 69%  
                        | Headache: 63%  
                        | Muscle pains: 60%  
                        | Chills: 43%  
                        | Joint pains: 45%  
                        | Fever: 15%  | Pain at the injection site: 49%  
                        | Headache: 39%  
                        | Fatigue: 38%  
                        | Muscle pains: 33%  
                        | Nausea: 14%  
                        | Fever: 9%  |
| **Storage†**          | Deep freeze (-80°C to -60°C)  
                        | -25°C to -15°C for up to 2 weeks | -25°C to -15°C  | 2-8 °C |

*The vaccine may be given up to 4 days early if necessary. If the second dose is missed during the recommended 3 or 4 week timeframe, it should be scheduled for administration up to 6 weeks (42 days) after the first dose. Early or late doses do not need to be repeated; the two-dose regimen is adequate.

† See below for the pertinent Fact Sheet for Healthcare Providers for specific vaccine storage and administration details.

## Resources:

**Pfizer-BioNTech vaccine**
- [FDA Fact Sheet for Healthcare Providers Administering Vaccine (Pfizer)](https://www.fda.gov/COVID-19-vaccine)
Moderna
- FDA Briefing Document – Moderna COVID-19 Vaccine
- CDC – Information About the Moderna COVID-19 Vaccine
- FDA Fact Sheet for Healthcare Providers Administering Vaccine (Moderna)

Johnson & Johnson
- FDA Briefing Document – Johnson & Johnson (Janssen) COVID-19 Vaccine
- CDC – Information About the Johnson & Johnson COVID-19 Vaccine
- FDA Fact Sheet for Healthcare Providers Administering Vaccine (Johnson & Johnson (Janssen))

Excerpted from the Vaccination section of the CCHCS Interim Guidance for Health Care and Public Health Providers: https://cchcs.ca.gov/covid-19-interim-guidance/

Revised: March 9, 2021